此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Gut Microbiome Profiles in Patients With Chemotherapy-induced Neuropathy in the RCT OzoParQT (NCT06706544). (OzoParQTmicrob)

2026年9月22日 更新者:Bernardino Clavo, MD, PhD

Evaluation of the Gut Microbiome Profiles in Patients With Chemotherapy-induced Peripheral Neuropathy Treated in the Randomized Clinical Trial With Ozone OzoParQT (NCT06706544).

Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating side effect of chemotherapy (CT), often requiring dose reductions or treatment interruptions, which can compromise efficacy of the planned CT (limiting its efficacy). Additionally, CIPN usually decreases patients' quality of life.

Unfortunately, effective treatments for CIPN are limited. Emerging evidence suggests potential benefits of rectal ozone therapy and points to a possible role of the gut microbiome in CIPN development and treatment response.

This observational study, ancillary to the randomized clinical trial (RCT) OzoParQT (NCT06706544), investigates the relationship between gut microbiome composition and CIPN severity in patients receiving rectal ozone therapy.

Primary Objectives:

To evaluate if gut microbiome profiles differ between patients:

  1. with and without symptomatic improvement of CIPN.
  2. receiving rectal ozone therapy and those receiving placebo.

Secondary Objectives:

To evaluate the relationship between gut microbiome composition and:

  1. Health-related quality of life,
  2. Anxiety and depression,
  3. Biochemical markers of oxidative stress and inflammation.

Main Trial Endpoints.

Changes from baseline at the end of ozone therapy (week 16) in:

  • Gut microbiome profile
  • Patient-reported numbness and tingling
  • Neuropathy severity (QLQ-CIPN20 scale)
  • Paresthesia toxicity grade (CTCAE v.5.0)

Secondary Trial Endpoints.

Changes from baseline at the end of ozone therapy (week 16) in:

  • Patient-reported quality of life (EQ-5D-5L questionnaire)
  • Quality of life (QLQ-C30 questionnaire)
  • Anxiety and depression levels (HADS questionnaire)
  • Biochemical markers of oxidative stress
  • Biochemical markers of inflammation

Trial Design:

This observational study will analyze data from patients enrolled in the randomized, triple-blind, placebo-controlled OzoParQT clinical trial (NCT06706544).

Trial Population in the OzoParQT trial (NCT06706544):

Adults (≥18 years) with any tumor type, experiencing CIPN-related paresthesias (numbness and/or tingling), with a toxicity grade ≥ 2 according to the Common Terminology Criteria for Adverse Events (CTCAE v.5.0) for ≥ 3 months.

Intervention in the OzoParQT trial (NCT06706544).

All patients will receive standard care for their CIPN symptoms plus 40 sessions of rectal insufflation of an O3/O2 gas mixture over 16 weeks:

  • Ozone group: O3/O2 concentration increasing from 10 to 30 µg/mL
  • Control-placebo group: O2 only (0 µg/mL O3)

Study Duration:

Each patient will participate in this study (OzoParQTmicrob) for 16 weeks, concurrent with the ozone therapy intervention. The total planned project duration is 60 months.

研究概览

详细说明

Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating side effect of chemotherapy (CT), often requiring dose reductions or treatment interruptions, which can compromise efficacy of the planned CT (limiting its efficacy). Additionally, CIPN usually decreases patients' quality of life.

Unfortunately, effective treatments for CIPN are limited. Emerging evidence suggests potential benefits of rectal ozone therapy and points to a possible role of the gut microbiome in CIPN development and treatment response.

This observational study, ancillary to the randomized clinical trial (RCT) OzoParQT (NCT06706544), investigates the relationship between gut microbiome composition and CIPN severity in patients receiving rectal ozone therapy.

Primary Objectives:

To evaluate if gut microbiome profiles differ between patients:

  1. with and without symptomatic improvement of CIPN.
  2. receiving rectal ozone therapy and those receiving placebo.

Secondary Objectives:

To evaluate the relationship between gut microbiome composition and:

  1. Health-related quality of life,
  2. Anxiety and depression,
  3. Biochemical markers of oxidative stress and inflammation.

Main Trial Endpoints.

Changes from baseline at the end of ozone therapy (week 16) in:

  • Gut microbiome profile
  • Patient-reported numbness and tingling
  • Neuropathy severity (QLQ-CIPN20 scale)
  • Paresthesia toxicity grade (CTCAE v.5.0)

Secondary Trial Endpoints.

Changes from baseline at the end of ozone therapy (week 16) in:

  • Patient-reported quality of life (EQ-5D-5L questionnaire)
  • Quality of life (QLQ-C30 questionnaire)
  • Anxiety and depression levels (HADS questionnaire)
  • Biochemical markers of oxidative stress
  • Biochemical markers of inflammation

Trial Design:

This observational study will analyze data from patients enrolled in the randomized, triple-blind, placebo-controlled OzoParQT clinical trial (NCT06706544).

Trial Population in the OzoParQT trial (NCT06706544):

Adults (≥18 years) with any tumor type, experiencing CIPN-related paresthesias (numbness and/or tingling), with a toxicity grade ≥ 2 according to the Common Terminology Criteria for Adverse Events (CTCAE v.5.0) for ≥ 3 months.

Intervention in the OzoParQT trial (NCT06706544).

All patients will receive standard care for their CIPN symptoms plus 40 sessions of rectal insufflation of an O3/O2 gas mixture over 16 weeks:

  • Ozone group: O3/O2 concentration increasing from 10 to 30 µg/mL
  • Control-placebo group: O2 only (0 µg/mL O3)

Study Duration:

Each patient will participate in this study (OzoParQTmicrob) for 16 weeks, concurrent with the ozone therapy intervention. The total planned project duration is 60 months.

研究类型

介入性

注册 (估计的)

42

阶段

  • 阶段2
  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

  • 姓名:Francisco Rodríguez-Esparragón, BSc, PhD
  • 电话号码:34928449288
  • 邮箱:afrodesp@gmail.com

学习地点

    • Las Palmas
      • Las Palmas、Las Palmas、西班牙、35019
        • 招聘中
        • Hospital Universitario de Gran Canaria Dr. Negrín, (FIISC)
        • 接触:
        • 接触:
          • Francisco Rodríguez-Esparragón, BSc, PhD
          • 电话号码:34928449288
          • 邮箱:afrodesp@gmail.com

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • 0. Patients who agree to participate in the randomized clinical trial OzoParQT, and who also agree to participate in this study of gut microbiota by providing stool samples.
  • 1. Adults > = 18 years old.
  • 2. Previous treatment with any chemotherapy because of any tumor.
  • 3. Clinical diagnosis of paresthesia (numbness, tingling) secondary to CIPN, with toxicity Grade > = 2 (according to the Common Toxicity Criteria for Adverse Events (CTCAE) from the National Cancer Institute of EEUU, v.5.0) for > = 3 months.
  • 4. Without neurotoxic chemotherapy > = 3 months.
  • 5. Cancer disease is stable or in remission.
  • 6. Life expectancy > = 6 months.
  • 7. Before enrollment, women of childbearing potential should obtain a negative result in the serum or urine pregnancy test at the screening visit and accept the use of appropriate contraceptive methods at least from 14 days before the first ozone therapy session up to 14 days after the last one.
  • 8. To sign and date the specific informed consent of both studies (OzoParQT and OzoParQTmicrob)

Exclusion Criteria:

  • 1. Age < 18 years.
  • 2. A woman who is lactating, pregnant, suspected of being pregnant, or a woman of childbearing potential who does not use adequate contraceptive methods.
  • 3. Suspected symptoms are due to diabetic or compressive neuropathy.
  • 4. Severe psychiatric disorders.
  • 5. Inability to complete the quality of life questionnaires.
  • 6. Elevation above 5 times the maximum limit of normal creatinine.
  • 7. Patient who is hemodynamic or clinically unstable or who requires urgent or short-term interventional measures.
  • 8. Neoplasia in progression requiring recent initiation of systemic treatment or maintenance with neurotoxic chemotherapy.
  • 9. Life expectancy (for any reason) < 6 months.
  • 10. Known allergy to ozone, known glucose 6 phosphate dehydrogenase (G6PD) deficiency, or hemochromatosis.
  • 11. Contraindications or impossibility for rectal ozone treatment or to attend regularly to the treatment.
  • 12. Not meeting each and every one of the inclusion criteria

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:放映
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:Ozone Group

Drug: Ozone (O3/O2). Treatment: Usual treatment + Ozone therapy by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 μg/ml; 40 sessions in 16 weeks.

Usual treatment (by their oncologist or hematologist) + Ozone therapy by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 μg/ml; 40 sessions in 16 weeks.

其他名称:
  • O3
  • 臭氧处理
  • O3/O2 混合气体
安慰剂比较:Oxygen Group (Placebo)

Drug: Oxygen (O2). Treatment: Usual treatment + Oxygen by rectal insufflation. O3/O2 concentration = 0 μg/ml (only O2); 40 sessions in 16 weeks.

Usual treatment (by their oncologist or hematologist) + Oxygen by rectal insufflation. O3/O2 concentration = 0 μg/ml (only O2); 40 sessions in 16 weeks.

其他名称:
  • 氧气

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change from baseline in gut microbiome profile, at the end of ozone therapy.
大体时间:16 weeks.

Analysis of gut microbiome profile at the end of ozone therapy regarding the basal profile.

16 weeks.
Change from baseline in "numbness and tingling" self-perceived by patients at the end of ozone treatment.
大体时间:16 weeks.

Self-reported evaluation of the percentage of "numbness and/or tingling" regarding the basal level. From 100% (basal level, 0% improvement) to 0% (no numbness and tingling, 100% improvement).

16 weeks.
Changes from baseline in the degree of neuropathy according to the QLQ-CIPN20 scale at the end of ozone treatment.
大体时间:16 weeks.

Changes from baseline in the degree of neuropathy according to the QLQ-CIPN20 scale at the end of ozone treatment (from the European Organization for Research & Treatment in Cancer (EORTC)). It is evaluated through 20 items grouped into 3 dimensions: sensory, motor, and autonomic. Range: each item is scored from 1 (nothing) to 4 (a lot). The total score for each dimension is transformed into a score from 0 to 100, with 0 being the best possible state and 100 being the worst.

16 weeks.
Changes from baseline in the Grade of toxicity of parestesias (numbness, tingling) according to the CTCAE v.5.0. scale at the end of ozone treatment.
大体时间:16 weeks.

Changes from baseline in the Grade of toxicity of paresthesias (numbness, tingling) according to the CTCAE v.5.0. scale (from the National Cancer Institute of EEUU). Range from: Grade = (asymptomatic or mild symptoms) to Grade 3 (severe symptoms, limiting self-care activities in daily life).

16 weeks.

次要结果测量

结果测量
措施说明
大体时间
Changes from baseline in the "Quality of Life" according to the QLQ-C30 questionnaire at the end of ozone treatment.
大体时间:16 weeks.

Changes from baseline in the "Quality of Life" according to the QLQ-C30 questionnaire (from the European Organization for Research & Treatment in Cancer (EORTC)). Self-reported evaluation of 30 items that measure several scales and symptoms. Range (after standardization): from 0 (worst for overall health and function, best for symptoms) to 100 (best for overall health and functions, worst for symptoms).

16 weeks.
Change from baseline in "Quality of Life" (using the EQ-5D-5L questionnaire) self-perceived by patients at the end of ozone treatment.
大体时间:16 weeks.

Self-reported evaluation of: a) 5 physical and emotional items scored in five levels, from 1 (Best: I have no problem) to 5 (worst: I have an extreme problem or I am unable to…) and b) additional self-assessment of health by a visual analog scale (0 = worst health patient can imagine, 100 = best health patient can imagine).

16 weeks.
Changes from baseline in levels of anxiety and depression according to the Hospital Anxiety and Depression Scale (HADS), at the end of ozone treatment.
大体时间:16 weeks.

Changes from baseline in levels of anxiety and depression according to the Hospital Anxiety and Depression Scale (HADS). HADS is a self-administered questionnaire that assesses 14 items/symptoms of anxiety (7) and depression (7) experienced by patients. Each item is scored from 0 (better, no alteration) to 3 (worse level of alteration). For each symptom (anxiety or depression), the overall score is from 0 (better, no anxiety or depression) to 21 (worse, very severe anxiety or depression).

16 weeks.
Changes from baseline in biochemical parameters of oxidative stress at the end of ozone treatment.
大体时间:16 weeks.

Changes in serum levels of superoxide dismutase, glutathione, glutathione peroxidase and free radicals.

16 weeks.
Changes from baseline in biochemical parameters of inflammation at the end of ozone treatment.
大体时间:16 weeks.

Changes in serum levels of pro-inflammatory cytokines.

16 weeks.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 学习椅:Bernardino Clavo, MD, PhD、Hospital Universitario de Gran Canaria Dr. Negrín, (FIISC), Las Palmas, Spain
  • 研究主任:Francisco Rodríguez-Esparragón, BSc, PhD、Hospital Universitario de Gran Canaria Dr. Negrín, (FIISC), Las Palmas, Spain
  • 首席研究员:Francisco Rodríguez-Esparragón, BSc, PhD、Hospital Universitario de Gran Canaria Dr. Negrín, (FIISC), Las Palmas, Spain
  • 首席研究员:Bernardino Clavo, MD, PhD、Hospital Universitario de Gran Canaria Dr. Negrín, (FIISC), Las Palmas, Spain
  • 首席研究员:Jacob Lorenzo-Morales, Prof、Instituto Universitario de Enfermedades Tropicales y Salud Publica de Canarias - Universidad de La Laguna (IUETSPC-ULL)

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年2月7日

初级完成 (估计的)

2029年12月31日

研究完成 (估计的)

2030年3月31日

研究注册日期

首次提交

2025年1月23日

首先提交符合 QC 标准的

2025年1月23日

首次发布 (实际的)

2025年1月29日

研究记录更新

最后更新发布 (实际的)

2026年9月25日

上次提交的符合 QC 标准的更新

2026年9月22日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • 2024-385-1
  • PI23/01324 (其他赠款/资助编号:Instituto de Salud Carlos III)
  • PIFIISC24/37 (其他赠款/资助编号:Fundación Canaria Instituto Investigación Sanitaria de Canarias (FIISC))
  • CIGC'23/24 (其他赠款/资助编号:Cabildo de Gran Canaria)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

It will be available (after request):

  • Individual participant data (IPD) that underlie the results reported in further articles, after deidentification
  • Data will be available after publication, ending 36 months following article publication.
  • They will be available for investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose.
  • Study protocol

Proposals should be directed to: bernardinoclavo@gmail.com To gain access, data requestors will need to sign a data access agreement.

IPD 共享时间框架

Data will be available after publication, ending 36 months following article publication.

IPD 共享访问标准

Data will be available for investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose.

- Study protocol

Proposals should be directed to: bernardinoclavo@gmail.com To gain access, data requestors will need to sign a data access agreement.

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 国际碳纤维联合会
  • 企业社会责任

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅